|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum IgA,IgM,and IgG responses in COVID-19显示文摘Currently,detecting SARS-CoV-2 RNAs is a standard approach for COVID-19 diagnosis.However,there is an urgent need for reliable and rapid serological diagnostic methods to screen SARS-CoV-2-infected people including those who do not have overt symptoms.Most emerging studies described serological tests based on detection of SARS-CoV-2-specific IgM and IgG.1–4 Although detection of SARS-CoV-2-specific IgA in serum has been reported in few papers,5,6 analyses of IgA levels in a larger number of COVID-19 patients are still lacking. | Huan Ma Weihong Zeng Hongliang He Dan Zhao Dehua Jiang Peigen Zhou Linzhao Cheng Yajuan Li Xiaoling Ma Tengchuan Jin | 2020 | Cellular & Molecular Immunology2020，17，7： | 12 |
| 2 | Pattern recognition receptors in zebrafish provide functional and evolutionary insight into innate immune signaling pathways显示文摘模式识别受体(PRR ) 和他们的发信号的小径在认出病原体以及损坏房间的各种各样的部件并且触发消除的煽动性的回答有必要角色入侵微生物和损坏房间。zebrafish 对病原体重重地依靠这些主要防卫机制。这里,我们考察在 zebrafish 表明小径的主要 PRR 天生的免疫系统并且在 zebrafish 和人比较这些发信号的小径揭示他们的进化关系并且更好理解他们的天生的有免疫力的防卫机制。 | Yajuan Li Yuelong Li Xiaocong Cao Xiangyu Jin Tengchuan Jin | 2017 | Cellular & Molecular Immunology2017，14，1： | 6 |
| 3 | Designing of improved drugs for COVID-19:Crystal structure of SARS-CoV-2 main protease M^(pro)显示文摘Recently,Zhang and colleagues published a study in Science which reports about the crystal structure of the main protease(Mpro,3CLpro)of SARS-CoV-21.The authors reported the X-ray structure of unliganded SARS-CoV-2 Mpro and its complex withα-ketoamide inhibitor after a modification from the previously designed inhibitor through incorporating P3-P2 amide bond into pyridone ring so as to increase its half-life in plasma.Finally the authors demonstrated that the crystal structure of Mpro provides a basis for designing of a potent inhibitor to the protease with a marked tropism to the lung and with ease of administration through inhalation. | Hylemariam Mihiretie Mengist Xiaojiao Fan Tengchuan Jin | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 3 |
| 4 | Asymptomatic patients and asymptomatic phases of Coronavirus Disease 2019(COVID-19):a population-based surveillance study显示文摘In this population-based study,we identified 307 confirmed COVID-19 cases from massive surveillance,including 129551 individuals screened at fever clinics or returning from Hubei and 3710 close contacts of confirmed COVID-19 patients.Among them,17 patients were asymptomatic at initial clinical assessment.These asymptomatic patients on admission accounted for a small proportion of all patients(5.54%)with relatively weak transmissibility,and the detection rate was 0.35 per 100 close contacts.Moreover,the dynamics of symptoms of the 307 patients showed that the interval from symptom remission to the final negativity of viral nucleic acid was 5.0 days(interquartile range 2.0 to 11.0 days),with 14 patients(4.56%)having re-detectable viral RNA after discharge.Overall;our findings suggested asymptomatic carriers and presymptomatic patients only accounted for a small proportion of COVID-19 patients.Also,the asymptomatic phase during recovery from COVID-19 implied that negativity in viral RNA is necessary as a de-isolation criterion and follow-up is recommended. | Xueying Zheng Sihui Luo Yong Sun Mingfeng Han Jian Liu Liangye Sun Liangming Zhang Ping Ling Yu Ding Tengchuan Jin Zhirong Liu Jianping Weng | 2020 | National Science Review2020，7，10： | 2 |
| 5 | Re-detectable positive SARS-CoV-2 RNA tests in patients who recovered from COVID-19 with intestinal infection显示文摘Dear Editor,Severe acute respiratory syndrome coronavirus 2(SARSCoV-2),a novel coronavirus that causes Coronavirus Disease 2019(COVID-19)(Yang and Wang,2020),has spread to more than 200 countries and infected more than 9,000,000 people as of Jun 2020.Tens of thousands of patients with COVID-19 have recovered and been discharged from hospital.However,there are reports of recovered patients who subsequently tested positive for SARSCoV-2 after discharge(re-detectable positive,RP)(An et al.,2020;Lan et al.,2020),and this has led to increasing focus on the mechanism(s)underlying RP. | Wanyin Tao Xiaofang Wang Guorong Zhang Meng Guo Huan Ma Dan Zhao Yong Sun Jun He Lianxin Liu Kaiguang Zhang Yucai Wang Jianping Weng Xiaoling Ma Tengchuan Jin Shu Zhu | 2021 | Protein & Cell2021，12，3： | 1 |
| 6 | Crystal structure of Ara h 3, a major allergen in peanut显示文摘 | Tengchuan Jin Feng Guo Yu-wei Chen Andrew Howard Yu-Zhu Zhang | 2009 | Molecular Immunology2009，，8： | 1 |
| 7 | Structures of the HIN domain: DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor显示文摘 | Tengchuan Jin Andrew Perry Jiansheng Jiang | 2012 | Immunity2012，36，： | 1 |
| 8 | Crystal structure of Ara h 3,a major allergen in peanut显示文摘 | JIN Tengchuan GUO Feng CHEN Yuwei | 2009 | Mol Immunol2009，46，89： | 1 |
| 9 | Crystal structure of Ara h 3, a major allergen in peanut显示文摘 | JIN Tengchuan GUO Feng CHEN Yuwei | 2009 | Molecular Immunology2009，46，89： | 1 |
| 10 | Crystal structure of Ara h3, a major allergen in peanut显示文摘 | JIN Tengchuan GUO Feng CHEN Yuwei | 2009 | Molecular Immunology2009，46，89： | 1 |
| 11 | Purification, crystallization and initial crystallographic characterization of peanut major allergen Ara h 3显示文摘 | JIN Tengchuan HOWARD A ZHANG Yuzhu | 2007 | Acta Crystallogr Sect F Stmct Biol Cryst Commun2007，63，10： | 1 |
| 12 | Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron显示文摘SARS-CoV-2 variants with adaptive mutations have continued to emerge,causing fresh waves of infection even amongst vaccinated population.The development of broad-spectrum antivirals is thus urgently needed.We previously developed two hetero-bivalent nanobodies(Nbs),aRBD-2-5 and aRBD-2-7,with potent neutralization activity against the wild-type(WT)Wuhan isolated SARS-CoV-2,by fusing aRBD-2 with aRBD-5 and aRBD-7,respectively.Here,we resolved the crystal structures of these Nbs in complex with the receptor-binding domain(RBD)of the spike protein,and found that aRBD-2 contacts with highly conserved RBD residues and retains binding to the RBD of the Alpha,Beta,Gamma,Delta,Delta plus,Kappa,Lambda,Omicron BA.1,and BA.2 variants.In contrast,aRBD-5 and aRBD-7 bind to less conserved RBD epitopes non overlapping with the epitope of aRBD 2,and do not show apparent binding to the RBD of some variants.However,when fused with aRBD-2,they effectively enhance the overal binding affinity.Consistently,aRBD-2-5-Fc and aRBD-2-7 Fc potently neutralized all of the tested authentic or pseudotyped viruses,incuding WT,Alpha,Beta,Gamma,Delta,and Omicron BA.1,BA.1.1 and BA.2.Furthermore,aRBD-2-5-FC provided prophylactic protection against the WT and mouse-adapted SARS CoV-2 in mice,and conferred protection against the Omicron BA.1 variant in hamsters prophylatically and therapeutically,indicating that aRBD-2-5-Fc could potentially beneft the prevention and treatment of COVID-19 caused by the emerging variants of concern.Our strategy provides new solutions in the development of broad-spectrum therapeutic antibodies for COVID-19. | Huan Ma Xinghai Zhang Peiyi Zheng Peter H.Dube Weihong Zeng Shaohong Chen Qingyu Cheng Yunru Yang Yan Wu Junhui Zhou Xiaowen Hu Yan Xiang Huajun Zhang Sandra Chiu Tengchuan Jin | 2022 | Cell Research2022，32，9： | 1 |
| 13 | A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is still rapidly spreading worldwide.Many drugs and vaccines have been approved for clinical use show efficacy in the treatment and prevention of SARS-CoV-2 infections.However,the emergence of SARS-CoV-2 variants of concern(VOCs),such as Delta(B.1.617.2)and the recently emerged Omicron(B.1.1.529),has seriously challenged the application of current therapeutics.Therefore,there is still a pressing need for identification of new broad-spectrum antivirals.Here,we further characterized a human antibody(58G6),which we previously isolated from a patient,with a broadly authentic virus-neutralizing activity that inhibits the Delta and Omicron variants with half-maximal inhibitory concentrations(ICso)of 1.69 ng/ml and 54.31 ng/ml,respectively.58G6 shows prophylactic and therapeutic effcacy in hamsters challenged with the Delta and Omicron variants through nasal delivery.Notably,a very low dosage(2 mg/kg daily)of 58G6 efficiently prevented Omicron variant replication in the lungs.These advantages may overcome the efficacy limitation of currently approved neutralizing antibodies that can be administered only by intravenous injection.In general,58G6 is a promising prophylactic and therapeutic candidate against current circulating VOCs and even future emerging mutants.To the best of our knowledge,58G6 is one of the most potent neutralizing antibodies against Omicron,with a broader spectrum than those approved for clinical use.58G6 could be developed as a nebulized therapy,which would be more cost effective and user friendly and enhance the clinical outcome comparedto thatobtainedwithdirect nasaldelivery. | Xinghai Zhang Huajun Zhang Tingting Li Shaohong Chen Feiyang Luo Junhui Zhou Peiyi Zheng Shuyi Song Yan Wu Tengchuan Jin Ni Tang Aishun Jin Chengyong Yang Guofeng Cheng Rui Gong Sandra Chiu Ailong Huang | 2022 | Signal Transduction and Targeted Therapy2022，7，9： | 1 |
| 14 | Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques显示文摘Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,and rapidly emerging variants,which have led to its rapid spread worldwide(Krammer 2020).Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus responsible for COVID-19,including vaccines based on messenger RNA(mRNA)(Polack et al.2020),viral vectors(Zhu et al.2020),recombinant proteins(Yang et al.2020),and inactivated SARS-CoV-2(Zhang et al.2021). | Dali Tong Mei Zhang Yunru Yang Han Xia Haiyang Tong Huajun Zhang Weihong Zeng Muziying Liu Yan Wu Huan Ma Xue Hu Weiyong Liu Yuan Cai Yanfeng Yao Yichuan Yao Kunpeng Liu Shifang Shan Yajuan Li Ge Gao Weiwei Guo Yun Peng Shaohong Chen Juhong Rao Jiaxuan Zhao Juan Min Qingjun Zhu Yanmin Zheng Lianxin Liu Chao Shan Kai Zhong Zilong Qiu Tengchuan Jin Sandra Chiu Zhiming Yuan Tian Xue | 2023 | Protein & Cell2023，14，1： | 0 |
| 15 | 3-dose of RBD vaccine is sufficient to elicit a long-lasting memory response against SARS-CoV-2 infection显示文摘Dear Editor,The spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)led to a global pandemic with 260 million infected people.A variety of vaccines,including the mRNA and recombinant vaccines,were developed to prevent the spread of the disease.1,2 There is an urgent need for testing the vaccine-induced long-term memory response based on the immunological principles and identifying the optimal combination of dose and injection manner to provide important information for clinical application. | Mengqing Cong Yunru Yang Haiyang Tong Ajmeri Sultana Shimu Baolong Wang Qing Li Fengyin Li Yi Yang Tengchuan Jin Bofeng Li | 2022 | Signal Transduction and Targeted Therapy2022，7，4： | 0 |
| 16 | Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA显示文摘Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in convalescent patients,convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients.12 We and others previously found a surprisingly early serum lgA antibody response in the COVID-19 patients.However,the relative contribution of the lgA antibody towards virus neutralization with respect to other antibody isotypes is unknown. | Weihong Zeng Huan Ma Chengchao Ding Yunru Yang Yong Sun Xiaoxue Huang Weihuang He Yan Xiang Yong Gao Tengchuan Jin | 2021 | Signal Transduction and Targeted Therapy2021，6，2： | 0 |
| 17 | Decline of SARS-CoV-2-specific IgG,IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge显示文摘Dear editor,The 2019 novel coronavirus(later renamed as SARS-CoV-2 in February 2020)infected over 12 million people globally by early July 2020,causing mild to severe COVID-19 in millions.Monitoring the levels of antibodies such as immunoglobin(Ig)G,M and A that are specific to SARS-CoV-2 and present in the blood provides not only an alternative method for diagnosing SARS-CoV-2 infection(including asymptomatic carriers),but also a simple way to monitor immune responses in convalescent patients or after vaccination.A high and persistent level of antibodies specific to SARS-CoV-2,especially those that can bind to and neutralize the virus,would be a strong indication that an immunized host could resist to SRAS-CoV-2 infection.Currently,there are no effective drugs to specifically prevent or cure SARS-CoV-2 infection;therefore,host immune responses and antibody-based therapeutics will continue to play important roles in combating and later preventing COVID-19. | Huan Ma Dan Zhao Weihong Zeng Yunru Yang Xiaowen Hu Peigen Zhou Jianping Weng Linzhao Cheng Xueying Zheng Tengchuan Jin | 2021 | Science China(Life Sciences)2021，64，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员